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analysis is not meaningful.
Themanuscript by the group of investigators fromPrincess
MargaretCancerCentre tellsus that allogeneic transplantation
is feasible for patients over age 60, that treatment-related
mortality can be signiﬁcant, and that long-term survival in a
highly selected group of patients in CR1 may be achieved by
one-third of patients. With such results, were postremission
allogeneic transplantation for all older patients with AML in
CR1 evaluated as a novel therapeutic, I am uncertainwhether
the survival outcome fromdiagnosiswouldwarrant regulatory
approval, as the impact on survival for all would likely be very
limited because so many are excluded at each step of AML
treatment. Does this statement suggest that we not utilize
allogeneic transplantation in older patients? Certainly not.
With sucha limited therapeutic armamentarium,andwith the
sense that biologic factorsmay affect outcome of AML therapy
in the older age population, practitioners must present the
uncertain possibilities of allogeneic transplantation to their
patients, as well as the certainty of unfavorable outcome
associated with so-called conventional therapy.
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Accepted 12 February 2014I read with great interest the report from Jodele et al.
describing the use of eculizumab for the treatment of severe
hematopoietic stem cell transplantationeassociated throm-
botic microangiopathy (HSCT-TMA) [1]. This report extends
the work previously done by this same group of investigators
that reported a high frequency of heterozygous CFHR3-
CFHR1 deletions and associated CFH autoantibodies in
children undergoing allogeneic hematopoietic stem cell
transplantation [2]. In this report, Jodele et al. report the
successful treatment of 4 of 6 pediatric patients with severe
HSCT-TMA characterized by multiorgan impairment, un-
controlled hypertension, and worsening renal function,
despite plasma exchange therapy, that recovered after
treatment with eculizumab, an antibody inhibitor ofterminal complement activity. Although the clinical re-
sponses alone in this cohort of patients are remarkable,
additional data reported in this manuscript, including the
use of total hemolytic complement activity (CH50) to
monitor the effectiveness of therapeutic complement
blockade and the relatively short course of therapy utilized,
are certainly thought provoking. Collectively, both publica-
tions support the hypothesis that complement dysregulation
may be central to the pathogenesis of HSCT-TMA, and they
provide the framework for future studies to better under-
stand the pathophysiology, risk factors, and ultimately the
treatment of HSCT-TMA related to both autologous and
allogeneic stem cell transplantation.
Although the report by Jodele et al. represents a signiﬁ-
cant improvement in our understanding of the pathophysi-
ology of HSCT-TMA, the ﬁndings in this report may
potentially be very important and applicable to other
complement-mediated diseases. There are increasing data to
suggest that the rate of improvement of renal injury in pa-
tients with atypical hemolytic uremic syndrome (aHUS) is
related to the time to initiate therapy with eculizumab, with
a shorter time to the initiation of eculizumab being associ-
ated with greater improvement in renal function [3,4].
However, as pointed out by Jodele et al., it may not be enough
to initiate therapy rapidly; rather, it may be more important
to rapidly achieve therapeutic trough levels of eculizumab
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ment activity. Four of the 6 patients treated had subthera-
peutic trough levels of eculizumab after the ﬁrst dose, using a
weight-based dosing algorithm. The only patient who ach-
ieved and maintained therapeutic eculizumab levels after
the ﬁrst dose in this report received higher than the rec-
ommended weight-based dose, which may, in part, explain
the faster clinical response seen in this patient. Eventually all
4 responding patients achieved therapeutic trough levels of
eculizumab, but all 4 patients required a higher dose than is
currently recommended for the treatment of aHUS. In the 2
nonresponding patients, eculizumab trough levels remained
subtherapeutic, providing 1 potential explanation for the
lack of clinical response to therapy. Therefore, the goal
should not be the rapid administration of the ﬁrst dose, but
rather to achieve therapeutic levels of eculizumab and
complement blockade as soon as possible. For more catabolic
or critically ill patients, increased doses of eculizumab may
be required. The failure to clinically respond to therapy with
eculizumab, therefore, may not always reﬂect the failure of
therapeutic complement blockade therapy, but rather the
failure to achieve therapeutic drug concentrations. Addi-
tionally, these data from this cohort of pediatric patients
with HSCT-TMA challenge the assumption that the dosing of
eculizumab is uniform across different disease states. It is
certainly plausible that differing underlying causes of com-
plement dysregulation may require unique dosing schedules
to achieve therapeutic complement blockade.
Two impediments to achieving therapeutic eculizumab
concentrations are the limited availability of eculizumab
drug levels and a turnaround time for results of roughly 1 to
2 weeks that may prevent the real-time dose adjustments
required to quickly achieve and maintain therapeutic drug
concentrations. Jodele et al. evaluated the relationship be-
tween eculizumab concentrations and CH50 levels and found
a strong correlation. A CH50 level of 0 to 3 complement
activity enzyme units was found to correspond to thera-
peutic eculizumab concentrations (>99 mg/mL), with a CH50count of 4 complement activity enzyme units reﬂecting
subtherapeutic eculizumab concentrations. CH50 testing is
readily available at most institutions with a turnaround time
that would bemore practical and amenable for its use in real-
time for eculizumab dose adjustments.
It is also important to note the sustained improvement
achieved after a discrete course of therapy with eculizumab
in these 4 responding patients. In contrast to patients with
paroxysmal nocturnal hemoglobinuria and aHUS who are
expected to require long-term or life-long therapy, all 4
successfully treated HSCT-TMA patients were able to safely
discontinue therapy after 4 to 15 weeks of treatment. This
implies that the complement dysregulation seen in patients
with HSCT-TMA may be transient and related to concurrent
infections or immune dysregulation related to the stem cell
transplantation. In this scenario, complement inhibition
therapy, in theory, may not be required long term, but rather
long enough to control the thrombotic microangiopathy
ﬁndings related to the transient risk factors associated with
hematopoietic stem cell transplantation.ACKNOWLEDGMENTS
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